Craig Slingluff headshot
CS

Craig L. Slingluff

Professor
Unit: School of Medicine
Department: Department of Surgery
Office location and address
Emily Couric Clinical Cancer Center
345 Crispell Drive, Room G713
Charlottesville, Virginia 22908
Education
BA, Echols Scholar, University of Virginia
MD, Medicine, University of Virginia School of Medicine, Charlottesville, VA
Fellowship, Melanoma Immunology, Duke University School of Medicine, Durham, NC
Resident, Surgery, Duke University School of Medicine, Durham, NC
Biography

Dr. Craig Slingluff is the Joseph Helms Farrow Professor of Surgery at UVA Health System, where he serves as the vice-chair for research in the Department of Surgery, director of the UVA Cancer Center Human Immune Therapy Center, and co-chair of the Melanoma Committee of ECOG. He has 20 years of experience as a surgical oncologist and as an independent investigator in cancer immunology and immunotherapy, all at UVA. 

His research work includes laboratory studies and clinical trials, focused primarily on developing melanoma vaccines and combination immunotherapy, with extensive correlative studies. Since 1996, he has run 19 investigator-initiated clinical trials, most of which have been for melanoma vaccines, especially involving melanoma peptides. These studies have all included intensive immunologic correlates based on evaluating immunologic response in multiple tissue compartments. A major focus of his work now is on characterizing the metastatic melanoma microenvironment, especially including the molecular mediators of immune dysfunction versus tumor rejection. 

As a surgical oncologist, he facilitates collection of human tumor tissue for research, and has collected a large human tissue resource for ongoing and future correlative studies. This includes tumor microarrays linked to clinical outcome data. He is dedicated to development of new technologies and therapies for melanoma and other cancers. He has mentored over 20 research fellows and he has been funded continuously by the National Cancer Institute for 20 years for his work in translational and clinical research.    

CA209-038. Biologic effects of PD-1 antibody BMS-936558 in Advanced Melanoma
Source: Bristol-Myers Squibb Company
January 07, 2013 – December 31, 2025
MD-INMD-HO A randomized Multicenter Phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with MK-3475 (anti-PD1) to CRT alone in patients with resectable pancreatic cancer
Source: Merck Sharp & Dohme Corp.
December 19, 2014 – April 30, 2024
MD-Surg_Prognostic Gene Expression Profiling and Adjuvant Therapy in Stage IIIA-B Cutaneous Melanoma (PERSONALize)
Source: Castle Biosciences, Inc.
February 16, 2021 – February 15, 2024
Enhanced Melanoma Vaccine Against Neoantigens and Shared Antigens by CD40 Activation and TLR Agonists
Source: U.S. DOD - Army - Medical Research Acquisition Act
July 15, 2019 – July 14, 2023
Slingluff Curevac Consulting Agreement
Source: CureVac AG
June 15, 2020 – June 14, 2023
MD-SURG Polynoma MAVIS Trial: An Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients with a High Risk of Recurrence (Protocol 103A-301)
Source: Polynoma, LLC
January 22, 2013 – February 28, 2023
Virginia Kincaid Cancer Research Fund
Source: Virginia Kincaid Charitable Trust
October 01, 2005 – December 31, 2021
DecisionDx-Melanoma Gene Expression Profile Test in Stage III Cutaneous Melanoma Patients with Complete Lymph Node Dissection
Source: Castle Biosciences, Inc.
October 23, 2018 – October 22, 2021
MD-SURG Postdoctoral Training Grant for MDs in Surgical Oncology Research
Source: U.S. NIH Cancer Institute
September 01, 2016 – August 31, 2021
Master Agreement
Source: Coalition Of Cancer Cooperative Groups
August 01, 2000 – July 31, 2021
Effects of vaccine adjuvants and skin microbiome in the vaccine-site microenvironment
Source: Cancer Research Institute
July 01, 2019 – June 30, 2021
OAQ RFA1 - Chromatin abnormalities and endogenous retrovirus expression as a novel biomarker of response to immune checkpoint therapy in low mutation burden cancers - Year 2
Source: Rutgers, The State University of New Jersey
June 25, 2020 – June 24, 2021
MD-SURG Promising biomarkers for Immune signatures and response to pembrolizumab
Source: Merck Sharp & Dohme Corp.
March 14, 2016 – April 30, 2021
MD-SURG Slingluff/Polynoma Consulting contract
Source: Polynoma, LLC
November 01, 2014 – November 01, 2020
Barrier Molecules and Their Impact on T cell Infiltration in Melanoma
Source: Cancer Research Institute
July 01, 2017 – June 30, 2020
OAQ RFA1 - Chromatin abnormalities and endogenous retrovirus expression as a novel biomarker of response to immune checkpoint therapy in low mutation burden cancers
Source: Rutgers, The State University of New Jersey
June 25, 2019 – June 24, 2020
MD-SURG Slingluff - Immatics Consulting Contract
Source: immatics biotechnologies GmbH
January 01, 2015 – December 31, 2019
Nano-Enhanced Vaccine for Melanoma
Source: Center For Innovative Technology
July 01, 2018 – December 31, 2019
Antibodies to Melanoma Vaccine Peptides
Source: U.S. NIH Cancer Institute
July 01, 2017 – December 31, 2019
Multicenter Selective Lymphadenectomy Trial-II
Source: John Wayne Cancer Institute
October 04, 2011 – August 31, 2019
MD-SURG Melanoma Vaccine for Helper T Cells Combined w/Targeted Therapies YR04
Source: U.S. NIH Cancer Institute
July 01, 2013 – June 30, 2019
MD-SURG Retention Integrins: Induction and Function on Cancer-Reactive T Lymphocytes
Source: Cancer Research Institute
July 01, 2015 – June 30, 2018
The association of cutaneous changes in the skin site of melanoma vaccination with improved circulating immune response
Source: Melanoma Research Foundation
February 01, 2017 – February 01, 2018
Mel55: T cell activation and immune cell function in melanoma patients treated with recMAGE-A3 and AS15 Immunological Adjuvant System
Source: GlaxoSmithKline Biologicals, SA
April 11, 2011 – December 31, 2017
MD-SURG Slingluff - Georgetown-Melanoma Trial
Source: Georgetown University
December 01, 2012 – November 30, 2017
MD-SURG Analysis of the Kinetics and Effects of Vemurafenib on Intratumoral and Host Immunity in Patients with Advanced BRAFV600 Mutant Melanoma: Implications for Combination with Immunotherapy
Source: Georgetown University
February 07, 2014 – November 30, 2017
MD-SURG Phase I Study of NY-ESO-1 Vaccine in Combination with Ipilimumab in Patients with Unresectable or Metastatic Melanoma for whom Treatment with Ipilimumab is indicated
Source: Ludwig Institute for Cancer Research Ltd.
September 11, 2013 – September 30, 2017
MD-SURG Slingluff FHCRC Lab
Source: Fred Hutchinson Cancer Research Center
September 01, 2013 – August 31, 2017
Postdoctoral Training Grant for MDs in Surgical Oncology Research
Source: U.S. NIH Cancer Institute
September 20, 2011 – June 30, 2017
Celldex Slingluff Consulting agreement
Source: Celldex Therapeutics, Inc.
June 06, 2016 – June 05, 2017
Protocol CDX1127-01
Source: Celldex Therapeutics, Inc.
December 01, 2011 – June 30, 2016
MD-SURG Melanoma Vaccine for Helper T Cells Combined with Targeted or Immune Therapies
Source: U.S. NIH Cancer Institute
July 01, 2013 – June 30, 2016
Combined Immunotherapy of melanoma with long peptides and TLR agonists
Source: Melanoma Research Alliance
November 01, 2011 – April 30, 2016
MD-SURG GSK DERMA 111482
Source: GlaxoSmithkline Beecham Pharmaceuticals
May 26, 2009 – March 31, 2016
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
GSK MEK116513
Source: GlaxoSmithkline Beecham Pharmaceuticals
November 18, 2012 – November 18, 2014
MD-SURG Melanoma Vaccines Using MHC-associated Peptides
Source: U.S. NIH Cancer Institute
June 01, 2008 – April 30, 2014
A Phase I study of the biological effects of BMS-936559 treatment in subjects with unresectable stage III or IV melanoma
Source: Bristol-Myers Squibb Company
April 03, 2012 – April 03, 2014
MD-SURG CLOSED
Source: Ludwig Institute for Cancer Research Ltd.
September 11, 2013 – September 11, 2013
  • 2011-2018 Best Doctors in America® List
  • 2015 One of America's Top Cancer Doctors, Newsweek®